Interestingly, CD4+ T cells engineered with the PD1/CD28 fusion construct provided enhanced T-cell help to improve the anti-tumour activity of CD8+ T cells in a pancreatic cancer and non-Hodgkin lymphoma model [46]. This evidence concerns the gene CD28 and neoplasm.